Home Inotrem S.A

Inotrem S.A

Inotrem Announces an Extension of Its License Agreement for the Biomarker Soluble TREM-1 to Cardiovascular Diseases

As of today, Inotrem owns exclusive rights for sTREM-1 in septic shock and cardiovascular diseases. This agreement will enable Inotrem to commercialize or sublicense for these indications any resulting test developed for sTREM-1.